New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Check below for free stories on MDT;COV;INTC;BSX;VRTX;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
September 18, 2014
12:18 EDTMDTNY AG announces national settlement with Medtronic for Medicaid violations
Attorney General Eric T. Schneiderman announced that 46 states and the District of Columbia have reach a settlement agreement with Minnesota-based company Medtronic to resolve claims under the False Claims Act that Medtronic improperly induced physicians to recommend Medtronic devices to treat cardiac rhythmic disease. New York led a national team composed of members from Oregon, Texas and California to negotiate the settlement. The federal government settled its matter in May of this year...The agreement requires Medtronic to pay the settling states $362,362, which will go to those statesí Medicaid programs. The matter was brought by a whistleblower, Adolfo Schroeder, and was filed in U.S. District Court for the Eastern District of California. The Attorney General would like to thank Mr. Schroeder for bringing this matter to the governmentís attention. Under the terms of the agreement, the New York Medicaid Program will receive $67,369.31. Reference Link
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information
06:50 EDTINTCIntel, Spreadtrum may enter partnership to develop x86 products, DigiTimes says
Intel is looking to promote x86 architecture to China chip designers and may enter a partnership with Spreadtrum, reports DigiTimes Research. The cooperation would allow Intel to fill some of its empty capacity while Spreadtrum would gain advantages from Intel's advanced manufacturing processes to reduce costs. Reference Link
September 17, 2014
16:01 EDTCOVCovidien raises quarterly dividend to 36c from 32c
Subscribe for More Information
09:08 EDTMDTMedtronic launches new Balloon Kyphoplasty Platform
Subscribe for More Information
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
07:43 EDTBSX, MDTBofA/Merrill to hold a conference
Subscribe for More Information
07:09 EDTVRTXVertex price target raised to $127 from $103 at Deutsche Bank
Subscribe for More Information
06:09 EDTMDTIntegra LifeSciences to acquire Medtronic instrumentation lines for $60M
Integra LifeSciences (IART) and Medtronic (MDT) announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60M in cash. Integra expects the transaction to close in Q4. Integra will acquire a portfolio of approximately 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments, as well as the St. Aubin le Monial, France manufacturing facility. Sales from the products being acquired totaled approximately $30M, two-thirds of which were generated outside the U.S. Integra expects to record approximately $27M-$30M in revenue and approximately 10c of adjusted EPS in calendar 2015 from this acquisition. The earnings accretion should rise after the first year once certain sales transitions are complete. The company expects the acquisition to contribute less than $5M in revenue and be neutral to earnings in Q4. The transition and integration is expected to be completed by 2H15.
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information
September 16, 2014
11:51 EDTCOV, MDTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
08:07 EDTMDTMedtronic drug-coated baloon shows strong clinical, economic benefit
Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics, or TCT, conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon, or DCB, from Medtronic augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for peripheral artery disease, or PAD, in leg arteries above the knee. The IN.PACT Admiral DCB remains an investigational medical device in the United States. No drug-coated balloon has yet received approval from the FDA. The new data come from the real-world IN.PACT Global study, the largest and most rigorous post-market evaluation of its kind for any peripheral artery intervention, and from an ongoing economic outcomes analysis of the U.S. phase of the landmark IN.PACT SFA trial. Together, the results show that the IN.PACT Admiral DCB is not only clinically superior, but also cost-effective for the treatment of atherosclerotic lesions in the superficial femoral artery, or SFA, or proximal popliteal artery, or PPA, at 12 months compared to standard percutaneous transluminal angioplasty, or PTA.
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
07:31 EDTJNJ, MDTEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
08:06 EDTMDTMedtronic announces SEEQ wearable cardiac monitoring system in U.S.
Subscribe for More Information
07:45 EDTBSX, MDTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
07:21 EDTMDTHeart Failure Society of America to hold annual meeting
Subscribe for More Information
07:19 EDTINTCSNIA to hold a conference
Subscribe for More Information
07:04 EDTCOVCovidien announces start of enrollment in two neurovascular trials
Covidien announced the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the companyís advanced neurovascular solutions. Baptist Medical Center in Jacksonville, Florida, treated the first patient enrolled in the PREMIER Prospective study, an international Investigational Device Exemption clinical study to evaluate the Pipeline embolization device in smaller unruptured intracranial aneurysms. Separately, Baptist Health Lexington in Kentucky, enrolled the first patient in the STRATIS Registry for Endovascular Stroke Devices, which will evaluate the use of all Covidien market-released stroke devices. The PREMIER study will enroll up to 141 patients in 20 global sites and is designed to assess the safety and effectiveness of the Pipeline device in the treatment of unruptured, small and medium wide-necked intracranial aneurysms. The STRATIS Registry, a prospective, multi-center, non-randomized, observational registry designed to evaluate the use of Covidien endovascular stroke devices in patients diagnosed with an acute ischemic stroke. Covidienís current endovascular stroke device in the U.S. is the Solitaireô 2 revascularization device. As many as 60 U.S. sites are expected to participate in the STRATIS Registry, which will enroll up to 1,000 patients to collect clinical outcomes for interventional stroke patients in a real world setting.
September 13, 2014
16:47 EDTMDTMedtronic CoreValve provides positive outcomes out two years in risky patients
Medtronic announced new data showing that transcatheter aortic valve replacement, TAVR, with the CoreValve System continued to provide safe and effective treatment, while maintaining exceptional rates of survival out to two years for patients who were considered too ill or frail to have their aortic valves replaced through traditional open-heart surgery. Without treatment, these patients had a 50% chance of death at one year.
September 12, 2014
15:03 EDTBSX, MDTSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 11, 2014
13:51 EDTINTCIntel tablet AP shipments could reach 7M units in 2H14, Digitimes reports
In the first half of 2014, Intel shipped approximately 1.5M tablet application processors, but Digitimes Research expects the company's shipments to total 7M units in the second half due to China brand vendors' and white-box players' full support, Digitimes reports. Reference Link
10:00 EDTMDTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Airgas (ARG) initiated with a Neutral at Northcoast... CBOE Holdings (CBOE) initiated with a Buy at Deutsche Bank... CME Group (CME) initiated with a Buy at Deutsche Bank... Colfax (CFX) initiated with a Neutral at Northcoast... Corporate Office Properties (OFC) initiated with an Overweight at Capital One... Edwards Lifesciences (EW) initiated with a Buy at Sterne Agee... Energen (EGN) initiated with a Buy at Deutsche Bank... Goodrich Petroleum (GDP) initiated with an Outperform at Cowen... GreenHunter Resources (GRH) initiated with a Hold at Stifel... GrubHub (GRUB) initiated with a Market Perform at Barrington... Illinois Tool Works (ITW) initiated with a Neutral at Northcoast... IntercontinentalExchange (ICE) initiated with a Hold at Deutsche Bank... JD.com (JD) initiated with a Buy at Brean Capital... Lincoln Electric (LECO) initiated with a Buy at Northcoast... Live Nation (LYV) initiated with a Buy at Jefferies... Medtronic (MDT) initiated with a Neutral at Sterne Agee... Midstates Petroleum (MPO) initiated with a Market Perform at Cowen... NASDAQ (NDAQ) initiated with a Hold at Deutsche Bank... Newfield Exploration (NFX) initiated with an Outperform at Iberia... Newpark Resources (NR) initiated with an Outperform at Credit Suisse... Nuverra Environmental (NES) initiated with a Buy at Stifel... Palo Alto (PANW) initiated with a Buy at Roth Capital... Petrobras (PBR) initiated with an Outperform at Cowen... RSP Permian (RSPP) initiated with a Hold at Deutsche Bank... Sensata (ST) initiated with an Equal Weight at Morgan Stanley... Stage Stores (SSI) initiated with a Neutral at Credit Suisse... Synergy Resources (SYRG) initiated with an Outperform at Cowen... TE Connectivity (TEL) initiated with an Overweight at Morgan Stanley... Twitter (TWTR) initiated with a Buy at Canaccord... Walter Investment (WAC) initiated with an Underweight at Barclays... Washington REIT (WRE) initiated with an Equalweight at Capital One... Yandex (YNDX) initiated with a Buy at Canaccord... Yara International (YARIY) initiated with a Neutral at Credit Suisse.
08:11 EDTMDTMedtronic Noncompliant Balloon Dilatation Catheter receives FDA clearance
Medtronic announced the FDA 510(k) clearance and launch of the NC Euphora Noncompliant Balloon Dilatation Catheter. Following drug-eluting stent implantation to reopen a narrowed artery, a noncompliant balloon is inflated with high pressure to ensure that the stent is fully apposed in order to facilitate transfer of the drug to the artery wall. Stent under-expansion has been defined as a major risk factor for both artery re-narrowing, or restenosis, and the potential formation of blood clots, known as stent thrombosis. Postdilatation with noncompliant balloons has been recommended to overcome these complications and provide optimal stent expansion after stent placement.
07:35 EDTINTCAntitrust suit over tech giants' hiring pushed back, WSJ reports
Subscribe for More Information
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
16:09 EDTMDTMedtronic initiated with a Neutral at Sterne Agee
Target $68.
16:00 EDTINTCIntel acquires Powerwave patent portfolio
Subscribe for More Information
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
09:32 EDTMDTMedtronic announces first U.S. implants in CoreValve Evolut R study
Subscribe for More Information
09:27 EDTVRTXVertex shares likely to advance further, says RBC Capital
Subscribe for More Information
07:37 EDTINTCIntel products look strong, says Wells Fargo
Subscribe for More Information
September 9, 2014
14:12 EDTINTCApple confirms wireless charging for Apple Watch
Subscribe for More Information
13:03 EDTINTCIntel head feels expensive tablet chip plan beneficial, Reuters says
Subscribe for More Information
11:47 EDTVRTXStocks with call strike movement; FSLR VRTX
First Solar (FSLR) March 80 call option implied volatility increased 2% to 42, Vertex (VRTX) January 105 call option implied volatility increased 6% to 41 according to IVolatility.
08:51 EDTINTCIntegrated Device says 'working closely' with Intel on wireless charging
Integrated Device Technology (IDTI) announced earlier at the Intel Developer Forum that it is working closely with Intel (INTC) on the development of wireless charging solutions to accelerate the delivery and adoption of the technology. The two companies, both board members of the Alliance for Wireless Power, will define, design and manufacture solutions that comply with the A4WP magnetic resonance standard. The new technology will offer the ability to charge both lower and higher power devices, from wearables and phones to tablets and PCs. The companies expect to have their technology in products in 2015, IDT stated.
07:29 EDTINTCUBM Canon to hold a summit
Subscribe for More Information
07:28 EDTINTCThe Money Event, Inc to hold a conference
Subscribe for More Information
07:17 EDTINTCThe Wireless Association to hold a conference
Subscribe for More Information
07:13 EDTINTCIntel to hold a forum
Annual Developers Forum: IDF 2014 to be held in San Francisco on September 9-11.
07:11 EDTINTCUBM Tech to hold a conference
Subscribe for More Information
06:42 EDTCOVLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
13:18 EDTINTCIntel 'Grantley' line could drive server processor unit growth, says Wells Fargo
Subscribe for More Information
13:15 EDTINTCIntel introduces Xeon processors for servers
Subscribe for More Information
11:05 EDTCOV, VRTXOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
07:26 EDTBSXMorgan Stanley to hold a conference
Subscribe for More Information
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.
September 5, 2014
16:12 EDTINTCFossil, Intel announce collaboration to develop innovation in wearable tech
Fossil Group (FOSL) and Intel Corporation (INTC) announced that they will be collaborating to further develop wearable technology for the fashion industry. Fossil Group will partner with Intel to identify, support and develop emerging trends in the wearable technology space. The companies will work together on emerging products and technologies that will be developed for the fashion-oriented consumer. In addition, Fossil Group will work closely with Intel Capital, Intelís global investment organization, to identify and evaluate co-investments in emerging technologies to accelerate industry innovation and stay at the forefront of the wearable consumer trend.
11:47 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
11:39 EDTINTCIntel launches Core M processor, available Holiday 2014
Subscribe for More Information
11:32 EDTINTCApple, Google, Adobe appeal court's rejection of hiring settlement, Reuters says
Subscribe for More Information
10:05 EDTJNJOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
10:05 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:41 EDTJNJJohnson & Johnson initiated with an Outperform at BMO Capital
Target $118.
08:22 EDTINTCNVIDIA lawsuits likely to have positive outcome, says JMP Securities
After NVIDIA (NVDA) filed lawsuits against Qualcomm (QCOM) and Samsung, JMP Securities thinks there is a good chance that NVIDIA will obtain a favorable ruling or settlement that is equal or greater to the $1.5B deal it cut with Intel (INTC),. The firm thinks that other companies, most notably Apple (AAPL), will launch talks with NVIDIA in the wake of the lawsuit. JMP Securities recommends buying NVIDIA ahead of upcoming Apple product refreshes and what it sees as accelerating growth trends for NVIDIA. The firm is upbeat about NVIDIA's new products and reiterates an Outperform rating.
06:11 EDTMDTMedtronic Linq device being underappreciated, says Citigroup
Citigroup believes the Street is underestimating the near-term potential of Medtronic's recently released Reveal Linq insertable cardiac monitor. Citi thinks the combination of the U.S. Corevalve rollout and Linq contribution will drive sales to the high end of the company's 3%-5% guidance. The firm raised its price target for shares to $74 from $73 and keeps a Buy rating on the stock.
05:41 EDTVRTXVertex upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Vertex Pharmaceuticals to Buy saying it sees a 90% probability of approval for the company's VX-809/Kalydeco combo for cystic fibrosis and a higher likelihood of M&A following the positive Phase 3 data in June. Goldman raised its price target for shares to $131 from $109.
September 4, 2014
11:05 EDTJNJJ&J unit Janssen receives orphan status for whipworm treatment
Subscribe for More Information
09:06 EDTINTCHP, Intel, Dell announce creation of Redfish industry standard
Subscribe for More Information
07:31 EDTINTCIntel management to meet with Deutsche Bank
Meeting to be held in Frankfurt on September 4 hosted by Deutsche Bank
06:40 EDTINTCApple, others restart discussions with tech staff in hiring suit, Reuters says
Subscribe for More Information
05:23 EDTJNJJohnson & Johnson to fast-track development of Ebola combination vaccine regimen
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use